E

Evotec SE
XETRA:EVT

Watchlist Manager
Evotec SE
XETRA:EVT
Watchlist
Price: 8.41 EUR 0.06% Market Closed
Market Cap: 1.5B EUR
Have any thoughts about
Evotec SE?
Write Note

Gross Margin
Evotec SE

13.7%
Current
22%
Average
44%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
13.7%
=
Gross Profit
106.5m
/
Revenue
777.1m

Gross Margin Across Competitors

Country DE
Market Cap 1.5B EUR
Gross Margin
14%
Country US
Market Cap 1.2T USD
Gross Margin
55%
Country US
Market Cap 202.3B USD
Gross Margin
41%
Country US
Market Cap 166.6B USD
Gross Margin
60%
Country KR
Market Cap 66.8T KRW
Gross Margin
49%
Country CH
Market Cap 38.4B CHF
Gross Margin
29%
Country US
Market Cap 38.8B USD
Gross Margin
55%
Country US
Market Cap 36.3B USD
Gross Margin
35%
Country US
Market Cap 27B USD
Gross Margin
59%
Country US
Market Cap 24.1B USD
Gross Margin
35%
Country CN
Market Cap 162.8B CNY
Gross Margin
40%
No Stocks Found

Evotec SE
Glance View

Market Cap
1.5B EUR
Industry
Life Sciences Tools & Services

Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.

EVT Intrinsic Value
14.13 EUR
Undervaluation 40%
Intrinsic Value
Price
E

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
13.7%
=
Gross Profit
106.5m
/
Revenue
777.1m
What is the Gross Margin of Evotec SE?

Based on Evotec SE's most recent financial statements, the company has Gross Margin of 13.7%.